Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

GARBER, Alan; KING, Allen; DEL PRATO, Stefano; SREENAN, Seamus; BALCI, MUSTAFA; MUNOZ-TORRES, Manuel; ROSENSTOCK, Julio; ENDAHL, Lars; FRANCISCO, Ann; HOLLANDER, Priscilla

doi:10.1016/s0140-6736(12)60205-0

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

Copy For Citation

GARBER A. J., KING A. B., DEL PRATO S., SREENAN S., BALCI M. K., MUNOZ-TORRES M., ...More

LANCET, vol.379, no.9825, pp.1498-1507, 2012 (SCI-Expanded)

Publication Type: Article / Article
Volume: 379 Issue: 9825
Publication Date: 2012
Doi Number: 10.1016/s0140-6736(12)60205-0
Journal Name: LANCET
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.1498-1507
Akdeniz University Affiliated: Yes

Abstract

Background Basal insulin therapy does not stop loss of beta-cell function, which is the hallmark of type 2 diabetes mellitus, and thus diabetes control inevitably deteriorates. Insulin degludec is a new, ultra-longacting basal insulin. We aimed to assess efficacy and safety of insulin degludec compared with insulin glargine in patients with type 2 diabetes mellitus.